Title:Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment
VOLUME: 23 ISSUE: 9
Author(s):Bijo Mathew*
Affiliation:Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041
Keywords:Chalcones, pharmacophore, monoamine oxidase, acetylcholinesterase, flurbiprofen, rivastigmine.
Abstract:Multi-functional design of ligands emerged as a new drug design paradigm of
Alzheimer’s disease (AD). Given the complexity of AD, the molecules showing dual inhibition of
monoamine oxidase (MAO) and acetylcholinesterase (AChE) with neuroprotective properties
could prevent the progressive neural degeneration effectively. Numerous studies documented that
chalcone is a privileged structural framework for the inhibition of both MAO and AChE. The
recent studies suggested that the development of chalcone candidates endowed with
pharmacophores of FDA approved drugs may become an active molecules in the field of current
AD research. The current perspective described the recent updates of chalcone moiety linked with
the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors
for the prophylactic agents for AD.
